Acquisition Context LATITUDE Pharmaceuticals was reportedly acquired by BioVie Inc. in 2016, which may present opportunities to re-engage legacy relationships, explore collaboration on reformulation or exclusive drug delivery IP, and identify any dormant programs that BioVie might be seeking to divest or optimize.

Niche Expertise As a CDMO specializing in insoluble and unstable drug formulations and 505(b)(2) NDA opportunities, LATITUDE offers a strong value proposition for biotech firms needing solvent- or stability-critical formulation work, opening potential partnerships for joint development, fee-for-service projects, or FTE-style engagements.

Reformulation IP The internal reformulation programs that generate out-license ready, proprietary delivery technologies present a clear pathway for licensing discussions, co-development deals, or milestone-driven partnerships with potential licensees seeking differentiated delivery platforms.

Growth Signals Revenue range of 10–25 million with a small-to-mid-size operation (11–50 employees) suggests a lean platform ideal for scalable, high-value formulation programs, strategic partnerships with larger CDMOs, or preferred supplier arrangements for tomorrow's pipeline needs.

Market Positioning Positioned among mid-to-large peers in contract formulation and manufacturing, LATITUDE can be explored as a strategic fit for big pharma or biotech clients seeking specialized expertise in insoluble compounds, stability-enabled programs, and rapid GMP formulation capabilities to de-risk translational programs.